BiotechTube
Home/NKILT Therapeutics/Henri Bayle, Ph.D.
HB

Henri Bayle, Ph.D.

CSO, CDO, Co-Founder

NKILT Therapeutics

Therapeutic Areas

Oncology

NKILT Therapeutics Pipeline

DrugIndicationPhase
CIR-NK cells (HLA-G target)Refractory leukemias and solid tumorsPre-clinical

Leadership Team at NKILT Therapeutics

RG
Raphaël G. Ognar, MSc, MBA
President, CEO, Co-Founder
View full NKILT Therapeutics profile